EANS-Adhoc: Sartorius AG rearranges Executive Board
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement.
24.07.2009
The Supervisory Board of the Sartorius AG decided unanimously in a meeting held on July 24th, 2009, to appoint Reinhard Vogt and Jörg Pfirrmann with immediate effect as new members of the Executive Board. At the same time the Supervisory Board and Dr. Günther Maaz amicably agreed by mutual consent that Dr. Maaz, who will turn 60 in September 2009, will resign from his position on the Executive Board of the Sartorius AG. The Supervisory Board thanks Dr. Maaz for his accomplishments for the benefit of the company over more than three decades in various positions, at last as a member of the Executive Board since 2002, and wishes him all the best for the future.
Within the new constellation of the Executive Board, every Member of the Board has cross-divisional responsibilities. Reinhard Vogt (53) will be in charge of Marketing, Sales and Service, while Jörg Pfirrmann (36) will take over the responsibility for Finance, IT and General Administration. The CEO, Dr. Joachim Kreuzburg (44), will be in charge of Operations, Legal Affairs, Internal Auditing and Corporate Communications as well as Human Resources and therefore will also take over the function of the Executive for Labor Relations. At the same time he will keep his current positions as the Chairman of the Board of Directors and the CEO of the Sartorius Subgroup Sartorius Stedim Biotech.
Reinhard Vogt, who has been with the Sartorius Group since 1983, has essentially shaped the strategic development of the Biotechnology Division and successfully achieved growth of sales revenues and profits. He will retain his present position as Executive Vice President for Marketing, Sales and Service of Sartorius Stedim Biotech.
Jörg Pfirrmann works since 1999 for Sartorius and was previously globally responsible for Group Finance. In the last years he has played a major part in orchestrating the success of key restructuring processes and acquisition projects of the Sartorius Group.
end of announcement euro adhoc
Further inquiry note:
Andreas Wiederhold
Team Leader Treasury & Investor Relations
Telefon: +49 (0)551 308-1668
E-Mail: andreas.wiederhold@sartorius.com
Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade